Wockhardt Ltd is a global pharmaceutical and biotechnology organization, providing affordable, high-quality medicines for a healthier world. The company is India's leading research-based global healthcare enterprise with relevance in the fields of Pharmaceuticals, Biotechnology and a chain of advanced Super Speciality Hospitals. The company has twelve manufacturing locations and there are five locations where research and development activities are carried out.
The company is headquartered in Mumbai, India. They have full-fledged operations in the USA, UK, Ireland and France. They also has their marketing presence in emerging markets of Russia, Brazil, Vietnam, Myanmar, Sri Lanka, and the African countries of Kenya, Ghana, Nigeria and Tanzania.
The company's output includes steriles (injectables), biopharmaceuticals, orals (tablets and liquids) and topicals (creams and ointments). The company's three principal products/ services include Spasmoproxyvon, Proxyvon and Methycobal. They have also launched three products in the Indian market, which include Biovac-B (hepatitis B vaccine), Wepox (erythropoietin) and Wosulin (recombinant insulin).
Wockhardt Ltd was incorporated on July 8, 1999. In the year 2000, the company launched the cardiac drug enalapril maleate in the US through their marketing joint venture with Sidmak Laboratories. Also, they set up a corporate training centre with modern and state-of-the-art facility under one roof at Aurangabad.
In the year 2001, the company terminated their three-year old marketing alliance with Sidmak Laboratories, one of the top ten generic Pharma companies in the US. Also, they entered into a strategic alliance with a Japanese firm Eisai Company Ltd to manufacture and market a neurology drug Methycobal.
In the year 2003, the company restructured their field organization to upgrade their competitiveness and productivity, launched new four speciality hospitals at their Mulund complex in Mumbai. Also, they acquired CP pharmaceuticals (Holdings) Ltd, along with their subsidiaries. The company launched Asia's first human recombinant insulin, making India the first Asian country to develop, manufacture and market the product. Also, they received USFDA approval for marketing bethanecol Chloride tablets in the US.
In the year 2004, the company acquired the German pharmaceutical company esparma GmbH for a consideration of Rs 49 crore. Also, they got USFDA nod for 6 manufacturing units.
In February 2005, the company launched India's first automatic insulin delivery device specially designed for the convenience of Indian diabetic patients. The company forged alliance with Kamineni Group to establish two world-class heart hospitals in the Hyderabad. Also, they received US FDA approval for marketing cefuroxime axetil in the US market. In the year 2006, the US FDA had approved the company's Waluj plant
In the year 2007, the company signed in-licensing pact with Crawford Healthcare of UK. They acquired Negma Laboratories, which is the fourth largest independent, integrated pharmaceutical groups in France, for an all-cash deal worth $ 265 million. In October 2007, they acquired the Morton Grove Pharmaceuticals, a leading liquid generic and speciality dermatology company in the US. Also, they inked an in-licensing agreement with the Italy-based Gnosis, to market SAMe (S-adenosyl methionine).
In the year 2008, the company approved demerger of their Research & Development business into a separate entity. Also, they launched the Cetirizine tablets in the USA. The company received the ANDA from the US FDA for marketing the tablets containing 5mg and 10mg Cetirizine Hydrochloride.
In February 2008, they received approval from the US FDA for marketing the tablets containing 250 mg, 500 mg and 600 mg Azithromycin. In August 2008, the company received tentative approval from the US FDA to make and sell Sumatriptan Succinate injection, in the strength of 6-mg/0.5 ml.
During the period January 2009 to March 2010, the company received 22 ANDA approval and launched eight new products, thereby expanding their product basket to 87. During the period, the company divested Animal Health Care Division to Vetoquinol, France. The business of Esparma GmbH was also divested to Mova GmbH.
During the year 2010-11, the company launched a total of 43 new products in India. In April 2011, as per the scheme of arrangement, the Nutrition Business of Vinton Healthcare Ltd, a wholly owned subsidiary of the company was de-merged into the company. The appointed date for the Scheme is January 1, 2011.
In January 2012, the company received final approval from the United States Food & Drug Administration (US FDA) for marketing 50 mcg nasal spray of Fluticasone which is used in treatment of allergic rhinitis.